A global license for the serological technology that detects COVID-19 antibodies will be provided royalty-free to poor and middle-income countries as part of a one-of-a-kind deal to boost production, announced World Health Organization (WHO) on Tuesday.
“The purpose of the license is to facilitate the rapid manufacture and commercialization of the CSIC’s COVID-19 serological test around the world,” the WHO said.
The four existing tests, which check for the presence of SARS-CoV-2 antibodies developed after infection or a vaccine dose, could also inform decisions about the need for boosters to protect against the disease, WHO said in a statement.
The tests are simple to use and even suitable for rural settings with basic laboratory infrastructure, according to WHO.
The non-exclusive license agreement with the Spanish National Research Council (CSIC), a public research institute offering the technology as a global public good, is the first trial license signed by the Medicines Patent Pool (MPP) of the WHO.
WHO Director-General Tedros Adhanom Ghebreyesus hailed the deal as he hoped that it would inspire other developers to share tools against COVID-19 which has killed 5.4 million people since the outbreak of the virus in the Chinese city Wuhan in December 2019.
“I urge developers of COVID-19 vaccines, treatments, and diagnostics to follow this lead and turn the tide on the pandemic and the devastating global inequalities this pandemic has brought to light,” said Tedros, according to Reuters.
Doctors without borders (MSF) also welcomed the agreement, noting that currently the WHO has only one antibody test using quantitative immunoassays (ELISA) manufactured by Roche Holding AG which can only be used with the own device of the Swiss-based drug manufacturer, reported Reuters.
“In order to overcome the monopoly of large diagnostic companies such as Roche, and to facilitate the production and supply of reliable ELISA antibody tests in all countries, the open license of CSIC to WHO C-TAP (COVID- 19 Technology Access Pool) is an important step forward,” the activist group said.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.